

# 高雄榮民總醫院

## 下咽癌診療原則

2026年01月14日 2026第一版

頭頸癌醫療團隊擬訂

注意事項：這個診療原則主要作為醫師和其他保健專家診療癌症病人參考之用。假如你是一個癌症病人，直接引用這個診療原則並不恰當，只有你的醫師才能決定給你最恰當的治療。

# 會議討論

上次會議:2025/02/19

本共識與上一版的差異

上一版	新版
2025 ver.1 無更改	<ol style="list-style-type: none"><li data-bbox="1006 432 1773 515">1. 新增Neoadjuvant pembrolizumab 與 IORT followed by adjuvant pembrolizumab</li><li data-bbox="1006 522 1591 605">2. 手術 Hemithyroidectomy更改為 Thyroidectomy</li><li data-bbox="1006 612 1785 736">3. (Page 4) Primary site: &lt;PR, option modified: Unresectable nodal disease 更改為Unresectable primary or nodal disease</li></ol>

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 1 (Ref. 1,2)

## WORK-UP

- History & PE
- Biopsy & Pathology
- Image
  - MRI\*or CT\* of H&N or PET/CT**
  - WBBS\* (if PET/CT not done)/ Abd.Sono\*/ CXR\***
  - PES
  - ± Chest CT(upper med.)  
(if PET/CT not done)
  - ± Neck sono  
(**\*與期別相關之主要檢查**)
- Dental evaluation
  - Panorex ± teeth extraction
- Multidisciplinary consultation  
(Fertility/reproductive, smoking cessation)
- Swallowing/speech
- HBV/HCV screening
- ± Pulmonary function if conservation surgery
- **± PD-L1 testing by immunohistochemistry(IHC)  
(combined positive score[CPS])**

## STAGING & TREATMENT


- [T1, N0 or Selected T2, N0, M0]  
*詳見 Page 2*
- [T2-3, any N; T1, N1-3, M0]  
*詳見 Page 3*
- [T4a, any N, M0]  
*詳見 Page 5*
- [T4b, any N, M0 or Inoperable status]  
*詳見 Page 6*
- M1  
*詳見 Page 7*

## FOLLOW-UP

- [Post-Tx within 3-6 months]
  - Baseline MRI or CT (PET)
  - Every 1-2 months: PE
- [2nd year after Tx]
  - Every 2-3 months: PE
- [3-5 years after Tx]
  - Every 4-8 months: PE
- [5 years after Tx]
  - Every 12 months: PE
- Every year:  
H&N MRI or CT, CxR, Bone scan & Abd. Sono, Neck Sono, PES, TSH, free T4(if RT, 6-12 months) as clinically indicated

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 2 (Ref. 1,2)




# Bil. ND was recommended in post-cricoid and posterior pharyngeal wall; however, bilateral ND was still suggested in patients with pyriform sinus tumor

\* Adverse features : Extranodal extension, positive or close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, lymphovascular invasion

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 3 (Ref. 1,2)

**Clinical T2-3,any N**  
**Clinical T1,N1-3**




<sup>#</sup>Bil. ND was recommended in post-cricoid and posterior pharyngeal wall; however, bilateral ND was still suggested in patients with pyriform sinus tumor

\* Adverse features: Extranodal extension, positive or close margins, pT3 or pT4 primary, N2 or N3 nodal disease, perineural invasion, lymphovascular invasion

**@ If neoadjuvant pembrolizumab received → consider RT + pembrolizumab (with cisplatin if ENE and/or positive margin) followed by adjuvant pembrolizumab**

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 4 (Ref. 1,2)



+ Primary site evaluated by CT or MRI(with contrast) of primary head and neck


# Bil. ND was recommended in post-cricoid and posterior pharyngeal wall; however, bilateral ND was still suggested in patients with pyriform sinus tumor

\* Adverse features : extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion


# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 5 (Ref. 1,2)

## Clinical T4a, any N



## Select T4a patients (high PS, multiple comorbidity or decline surgery)



# Neck dissection level 依primary部位及cN status而定。

\* Adverse features: Extranodal extension, positive or close margins, pT3 or pT4 primary, N2 or N3 nodal disease, perineural invasion, lymphovascular invasion

@ If neoadjuvant pembrolizumab received → consider RT + pembrolizumab (with cisplatin if ENE and/or positive margin) followed by adjuvant pembrolizumab

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 6 (Ref. 1,2)

**Inoperable status: T4b, any N/ Unresectable primary or nodal disease/ Unfit for surgery**

Management

**Clinical trial preferred**

**PS 0-1**

CCRT 註1-2

Induction C/T註3 + RT or CRT註1-2

**PS 2**

**CCRT(preferred)註1-2**

RT註1

**PS 3-4**

Palliative RT註1

Single agent palliative C/T(**PS 3 only**)註3

Best supportive care

ECOG Performance Status 0-1註6


ECOG Performance Status 2

ECOG Performance Status 3-4

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療 Ver.1 修訂於 2026.01.14 Page 7 (Ref. 15-17)


## Treatment



1. PS 0-1若治療無效，除 best supportive care 外可再考慮systemic therapy, clinical trial or palliative RT
2. PS 2-3 single agent systemic therapy 若治療無效，除 best supportive care 外可再考慮 alternate single agent systemic therapy or palliative RT

# Carcinoma of Hypopharynx


高雄榮民總醫院 臨床診療 Ver.1 增訂於 2026.01.14 Page 8 (Ref. 1,2)



# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療 Ver.1 增訂於 2026.01.14 Page 9 (Ref. 1,2)

## Treatment



1. PS 0-1若治療無效，除 best supportive care 外可再考慮systemic therapy, clinical trial or palliative RT
2. PS 2-3 single agent systemic therapy 若治療無效，除 best supportive care 外可再考慮 alternate single agent systemic therapy or palliative RT

# Carcinoma of Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 10 (Ref. 3-5)

註1

## Principles of Radiotherapy

### Definitive Radiotherapy

- Primary and gross adenopathy: 66 - 74Gy (2.0-2.2 Gy/fraction)
- Low to intermediate risk: 44 - 50 Gy (2.0 Gy/fractions) in 3D RT, 54- 63 Gy (1.6-1.8 Gy/fractions)

### Postoperative Radiotherapy

- Preferred interval between operation and radiotherapy is  $\leq 6$  weeks.
- High risk(adverse feature): 60 - 66 Gy (2.0 Gy/fraction)
- Low to intermediate risk: 44 - 50 Gy (2.0 Gy/fractions) in 3D RT, 54- 63 Gy (1.6-1.8 Gy/fractions)

### CCRT or RT

- RT alone if old age, impaired renal function, poor condition or refused chemotherapy
- High risk: Typically 70 Gy (2.0 Gy/fraction)
- Low to intermediate risk: 44 - 50 Gy (2.0 Gy/fractions) in 3D RT, 54- 63 Gy (1.6-1.8 Gy/fractions)

### Palliative RT

- Indicated in: Relieve local symptoms, prevent debilitation such as spinal cord compression and pathological fracture, achieve durable locoregional control.

# Carcinoma of Hypopharynx

註2 高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 11 (Ref. 6-10)

## Principles of Chemotherapy

## Concurrent with RT

### Regimen 1: q3w CDDP ± Cetuximab<sup>註5</sup> + RT

- Cisplatin (80-100mg/ m<sup>2</sup>) q3w during R/T
- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, then Cetuximab(250mg/ m<sup>2</sup>) maintain dose D1 + Cisplatin (80-100mg/ m<sup>2</sup>) q3w D2 during R/T

### Regimen 2: Weekly CDDP ± Cetuximab<sup>註5</sup> + RT

- Cisplatin (30-40mg/ m<sup>2</sup>) weekly during R/T
- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, and then Cisplatin (30-40mg/ m<sup>2</sup>) weekly D1 + Cetuximab(250mg/ m<sup>2</sup>) maintain dose D2 during R/T

### Regimen 3: q3w Carboplatin<sup>註5</sup> ± Cetuximab<sup>註5</sup> + RT

- Carboplatin (AUC x 5mg) q3w during R/T
- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, then Cetuximab(250mg/ m<sup>2</sup>) maintain dose D1 + Carboplatin (AUC x 5mg) q3w D2 during R/T

### Regimen 4: Weekly Cetuximab<sup>註5</sup> + RT

- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, then Cetuximab(250mg/ m<sup>2</sup>) maintain dose during RT

### Regimen5: Carboplatin + 5-FU + Hydroxyurea (CCr < 60) + RT

- Carboplatin (AUC x 1.25mg) D1-D4
- Fluorouracil (5-FU) (850mg/m<sup>2</sup>) D1-D4
- Hydroxyurea 1CAP BID D1-D5

### Regimen6: Cisplatin + 5-FU + Hydroxyurea + RT

- Cisplatin(20mg/ m<sup>2</sup>) D1-D4
- Fluorouracil (5-FU) (850mg/m<sup>2</sup>) D1-D4
- Hydroxyurea 1CAP BID D1-D5

### Regimen 7: Doxetaxel + RT

- Doxetaxel (60g/m<sup>2</sup>) D1, if cisplatin not eligible

# Carcinoma of Hypopharynx

註3

高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 12 (Ref. 11-15)

## Regimens of Chemotherapy

Induction/neoadjuvant, adjuvant, 建議1-4cycles

**Regimen 1 (First line): q3-4 weeks T<sup>註5</sup> + P ± F (5-FU or UFUR) ± weekly Cetuximab<sup>註5</sup>**

- Taxotere(60 mg/ m<sup>2</sup>) D1
- Cisplatin(60-75 mg/ m<sup>2</sup>) D1
- Fluorouracil (5-FU) (600-750mg/m<sup>2</sup>) D2-D5 or **UFUR**
- Cetuximab (400mg/ m<sup>2</sup>) loading dose first week, then Cetuximab (250mg/ m<sup>2</sup>) maintain dose

**Regimen 2 (First line): q3 weeks Pembrolizumab<sup>註5</sup> (200mg, if CPS ≥ 1)**

- Neoadjuvant 2 cycles + concurrent 3 cycles followed by adjuvant 12 cycles

**Regimen 3: q3-4 weeks Platinum ± F (5-FU or UFUR) ± weekly Cetuximab<sup>註5</sup>**

- Cisplatin(80-100mg/ m<sup>2</sup>) D1 or Cisplatin (20mg/ m<sup>2</sup>) D1-D5 or Carboplatin (AUC x 5mg) D1
- Fluorouracil (5-FU) (600-1000mg/m<sup>2</sup>) or **UFUR** D2-D5
- Cetuximab(400mg/m<sup>2</sup>) loading dose first week, then weekly Cetuximab (250mg/ m<sup>2</sup>)

# Carcinoma of Hypopharynx

註3

高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 13 (Ref. 11-15)

## Regimens of Chemotherapy

Induction/neoadjuvant,, adjuvant, 建議1-4cycles

### Regimen 4: weekly Cetuximab<sup>註5</sup>

- Cetuximab (400mg/ m<sup>2</sup>) loading dose first week, then Cetuximab (250mg/ m<sup>2</sup>) maintain dose

### Regimen 5: oral Fluorouracil

- Ufur cap (tegafur 100mg+uracil 224mg) 2# BID-TID  
(可作為取代iv-formed 5-FU之替代藥物)

### Regimen 6: weekly Methotrexate

- Methotrexate (40-60mg/ m<sup>2</sup>)

# Carcinoma of Hypopharynx

註4

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 14 (Ref. 16,17)

## Regimens of Chemotherapy

### Recurrent, unresectable, metastatic \*

#### Regimen 1 (First line): q3 weeks Pembrolizumab<sup>註5</sup> ± Platinum ± F

- Pembrolizumab(200mg) D1
- Cisplatin(80-100mg/m<sup>2</sup>) D1 or Cisplatin (20mg/ m<sup>2</sup>) D1-D5 or Carboplatin (AUC x 5mg) D1
- Fluorouracil (5-FU) (600-1000 mg/m<sup>2</sup>) D2-D5

#### Regimen 2 (First line): q3 weeks Pembrolizumab<sup>註5</sup>

- Pembrolizumab(200mg) D1 (if CPS ≥ 1)

#### Regimen 3 (Subsequent line): q2 weeks Nivolumab<sup>註5</sup>

- Nivolumab(3mg/kg) D1

#### Regimen 4 (Subsequent line): q3 weeks Pembrolizumab<sup>註5</sup>

- Pembrolizumab(200mg) D1 (if disease progression on or after platinum therapy)

#### Regimen 5: q3-4 weeks Platinum ± F ± weekly Cetuximab<sup>註5</sup>

- Cisplatin(80-100mg/ m<sup>2</sup>) D1 or Cisplatin (20mg/ m<sup>2</sup>) D1-D5 or Carboplatin (AUC x 5mg) D1
- Fluorouracil (5-FU) (600-1000 mg/m<sup>2</sup>) D2-D5
- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, then weekly Cetuximab (250mg/ m<sup>2</sup>)

#### Regimen 6: q3 weeks Pembrolizumab<sup>註5</sup> + Platinum + Doxetacel

- Pembrolizumab(200mg) D1
- Cisplatin(80-100mg/ m<sup>2</sup>) D1 or Cisplatin (20mg/ m<sup>2</sup>) D1-D5 or Carboplatin (AUC x 5mg) D1
- Taxotere(60 mg/ m<sup>2</sup>)

\* 針對Recurrent or persistent disease with M1 , 建議NGS

# Carcinoma of Hypopharynx

註4

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 15 (Ref. 16,17)

## Regimens of Chemotherapy

### Recurrent, unresectable, metastatic \*

#### Regimen 7: q3-4 weeks T ± Platinum ± weekly Cetuximab<sup>註5</sup>

- Taxotere(60 mg/ m<sup>2</sup>) D1
- Cisplatin(60-75 mg/ m<sup>2</sup>) D1 or Carboplatin (AUC x 5mg) D1
- Cetuximab(400mg/ m<sup>2</sup>) loading dose first week, then weekly Cetuximab (250mg/ m<sup>2</sup>)

#### Regimen 8: cisplatin+ epirubicin+ 5-FU+ Leucovorin

- Cisplatin (60 mg/ m<sup>2</sup>) D1
- Epirubicin (50 mg/ m<sup>2</sup>) D1
- Fluorouracil (5-FU) (2000 mg/m<sup>2</sup>) D1

#### Regimen 9: q2 weeks Bevacizumab

- Bevacizumab (200 mg/ m<sup>2</sup>) D1

#### Regimen 10: weekly Gemcitabine

- Gemcitabine (1000 mg/m<sup>2</sup>) D1

\*針對Recurrent or persistent disease with M1 , 建議NGS

# Carcinoma of Hypopharynx

註5

高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 16

## 特殊用藥健保給付規定

### Taxotere

- 頭頸部癌，限局部晚期且無遠端轉移之頭頸部鱗狀細胞癌且無法手術切除者。
- 與Cisplatin 及5-FU 併用，作為放射治療前的引導治療，限使用四個療程。

### Cetuximab

- 限與放射線療法合併使用於局部晚期之口咽癌、下咽癌及喉癌患者，使用總療程以接受8次輸注為上限，需經事前審查核准後使用，且符合下列條件之一：
  1. 年齡  $\geq 70$  歲
  2. Ccr  $< 50$ ml/min
  3. 聽力障礙者 (聽力障礙定義為500Hz、1000Hz、2000Hz 平均聽力損失大於25 分貝)
  4. 無法耐受platinum-based 化學治療
- 限無法接受局部治療之復發及/或轉移性頭頸部鱗狀細胞癌，且未曾申報 cetuximab 之病患使用。使用總療程以18週為限，每9週申請一次，需無疾病惡化情形方得繼續使用。

### Carboplatin

- 限腎功能不佳 (CCr  $< 60$ ) 或曾作單側或以上腎切除之惡性腫瘤患者使用。

# Carcinoma of Hypopharynx

註5

高雄榮民總醫院 臨床診療指引 Ver.1修訂於 2026.01.14 Page 17

## 特殊用藥健保給付規定

### Pembrolizumab(一、二線)、Nivolumab(二線)

- 二線: 先前已使用過 platinum 類化學治療失敗後，又有疾病惡化的復發或轉移性頭頸部鱗狀細胞癌成人患者。本類藥品與 cetuximab 僅能擇一使用，且治療失敗時不可互換。
  - 一線: 先前沒有接受過全身性治療(距離CCRT或之前使用platin類藥物 >6 months)，且無法手術切除的復發性或轉移性第三、四期頭頸部鱗狀細胞癌成人患者。
- 符合下列條件：
1. 病人身體狀況良好(ECOG ≤ 1)
  2. NYHA (the New York Heart Association) Functional Class I 或 II
  3. GOT < 60U/L 及 GPT < 60U/L，且 T-bilirubin < 1.5mg/dL；Creatinine < 1.5mg/dL，且 eGFR > 60mL/min/1.73m<sup>2</sup>
  4. 二線: PD-L1 表現量 TPS ≥ 50%，TC ≥ 10%
  5. 一線: PD-L1 表現量 CPS ≥ 20%
- 初次申請以 12 週為限，申請時需檢附以下資料：病理或細胞檢查報告、生物標記(PD-L1)表現量檢測報告、病人身體狀況良好(ECOG ≤ 1)及心肺與肝腎功能之評估資料、符合 i-RECIST 定義之影像檢查及報告(上述影像檢查之給付範圍不包括PET)、先前已接受過之治療與完整用藥資料、使用免疫檢查點抑制劑之治療計畫(treatment protocol)。
- 用藥後每 12 週評估一次，以 i-RECIST 或 mRECIST 標準評定反應，依下列原則給付：
- I. 有療效反應者(PR 及 CR)得繼續使用；
  - II. 出現疾病惡化(PD)或出現中、重度或危及生命之藥物不良反應時，應停止使用；
  - III. 疾病呈穩定狀態者(SD)，可持續再用藥 4 週，並於 4 週後再次評估，經再次評估若為 PR、CR 者，得再繼續使用 12 週。若仍為 SD 或已 PD 者，應停止使用。

# Carcinoma of Hypopharynx

註6

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 18

## Eastern Cooperative Oncology Group (ECOG) Performance Status

Grade	Description	Suggestion
0	Normal activity fully ambulatory (無症狀)	按照標準化療評估及療程。
1	Symptoms, but nearly fully ambulatory (有症狀，完全步行，但對生活無影響)	按照標準化療評估及療程。
2	Some bed time, but needs to be in bed less than 50% of normal daytime (躺在床上的時間<50%)	按照標準化療評估及療程。
3	Needs to be in bed more than 50% of normal daytime (躺在床上的時間>50%)	可視情況考慮停止化學治療。
4	Unable to get out of bed (長期完全臥床)	建議停止化學治療。
5	Dead	

# Carcinoma of the Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 19

## References

1. **NCCN Clinical Practice Guidelines in Oncology – Head and Neck Cancers Version 1. 2026**
2. Kodaira T, Kagami Y, Machida R, et al. Long-term follow-up of a randomized controlled trial on accelerated radiation therapy versus standard fractionated radiation therapy for early glottic cancer (JCOG0701A3). *Int J Radiat Oncol Biol Phys* 2023;117:1118-1124
3. Hsieh MC, Wang CC, Yang CC, Lien CF, Wang CC, Shih YC, Yeh SA, Hwang TZ. Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis. *Biology (Basel)*. 2021 Oct 8;10(10):1011. doi: 10.3390/biology10101011. PMID: 34681110; PMCID: PMC8533478.
4. AJCC (Amin M, Edge S, Greene F, et al. *AJCC Cancer Staging Manual*, 8th ed. New York: Springer; 2017
5. Rodell RM, Steiner W, Muller RM, et al. Endoscopic laser surgery of early glottic cancer: involvement of the anterior commissure. *Head Neck* 2009;31:583-592. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19132720>.
6. Zouhair A, Azria D, Coucke P, et al. Decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior commissure extension. *Strahlenther Onkol* 2004;180:84-90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14762660>.
7. Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. *Eur Arch Otorhinolaryngol* 2009;266:1333-1352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19597837>.
8. Warner L, Chudasama J, Kelly CG, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. *Cochrane Database Syst Rev* 2014:Cd002027. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25503538>.
9. Warner L, Lee K, Homer JJ. Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes. *Clin Otolaryngol* 2017;42:629-636. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27863075>.
10. Mo HL, Li J, Yang X, et al. Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and metaanalysis. *Lasers Med Sci* 2017;32:461-467. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27966051>.
11. Yoo J, Lacchetti C, Hammond JA, Gilbert RW. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: a systematic review. *Head Neck* 2014;36:1807-1819. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24115131>.
12. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 2013;31:845-852. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23182993>.
13. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091-2098. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14645636>.
14. Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation. *J Natl Cancer Inst* 2016;108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26681800>.
15. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst* 2009;101:498-506. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19318632>.
16. Semrau S, Schmidt D, Lell M, et al. Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx. *Oral Oncol* 2013;49:454-460. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23321550>.

# Carcinoma of the Hypopharynx

高雄榮民總醫院 臨床診療指引 Ver.1 修訂於 2026.01.14 Page 20

## References

17. Stokes WA, Jones BL, Bhatia S, et al. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. *Cancer* 2017;123:600-608. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27727461>.
18. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 2013;31:845-852. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23182993>.
19. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol* 2003;21:92-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12506176>.
20. Sun XS, Michel C, Babin E, et al. Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. *Future Oncol* 2018;14:877-889. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29578359>.
21. Bonomo P, Greto D, Desideri I, et al. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? *Oral Oncol* 2019;93:1-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31109688>.
22. Bates JE, De Leo AN, Morris CG, et al. Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: single-institution outcomes. *Head Neck* 2019;41:2309-2314. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30788878>.
23. Yamazaki H, Nishiyama K, Tanaka E, et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. *Int J Radiat Oncol Biol Phys* 2006;64:77-82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16169681>.
24. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24-35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20530316>.
25. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008;100:261-269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18270337>.
26. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. *J Clin Oncol* 2010;28:4142-4148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20697079>.
27. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. *J Clin Oncol* 2014;32:3365-3373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24958820>.
28. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. *Ann Oncol* 2011;22:1071-1077. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21317223>.
29. Sritippho T, Chotjumlong P, Iamaroon A. Roles of human papillomaviruses and p16 in oral cancer. *Asian Pac J Cancer Prev* 2015;16:6193-6200. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26434816>.
30. Uppaluri R, Campbell KM, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clin Cancer Res*. 2020 Oct 1;26(19):5140-5152. Available at: <https://pubmed.ncbi.nlm.nih.gov/32665297>.
31. Ravindra U, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. *N Engl J Med* 2025;393:37-50. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2415434>